Abstract
The vascular endothelial growth factor 165 (VEGF165) is a quintessential biomarker in cancers. An easy and precise tool for the early detection of malignancies is required for rapid care and metastasis prevention. Cobalt-based metal–organic framework (Co-BTC-GO-MOF) nanoparticles have been used as a signal carrier for the anti-VEGF165 signaling antibody. Cobalt-based MOF was synthesized using cobalt (Co), benzene-1,3,5-tricarboxylate (BTC), and graphene oxide (GO) applying a hydrothermal method. Structure, compositions, size and morphology of the qualified sensor are determined by using distinctive analytical techniques. The Co-MOF nanoparticles are found to be thermostable, as revealed by thermal stability assay. The strategy utilises an impedimetric and differential pulse voltammetry (DPV) techniques in the presence of the [Fe(CN)6]3−/4− redox system. Compared to earlier results, this assay resulted in higher sensitivity with the limit of detection (LOD) found to be 5.23 pM in a 0.01 M buffer solution of pH 7.4 using linear scale voltammetry at room temperature. The resulting Co-BTC-GO-MOF immunosensor shows high responsiveness and selectivity in detecting VEGF165 in real-time serum samples of cancer patients. The electrochemical performance studies confirm that the intended proposed immunosensor could pave the way for the future advancement of high-performance, sensitive, reproducible and robust immunosensors for the cost-effective and initial phase detection of cancer in the future.
Highlights
Vascular endothelial growth factor (VEGF) is a hypoxiainducible protein that results from alternate splicing of the VEGF gene.[1]
The characteristic peak at 1700 cmÀ1 for all the metal–organic frameworks (MOFs) was attributed to C]O present in the structures, while at about 1245 cmÀ1 was assigned to C–O
A novel and ultrasensitive immunosensor has been successfully developed for the detection of vascular endothelial growth factor 165 (VEGF165) using Co-BTC-graphene oxide (GO)-MOFs as the biosensing platform
Summary
Vascular endothelial growth factor (VEGF) is a hypoxiainducible protein that results from alternate splicing of the VEGF gene.[1]. Different CNS disorders, such as Parkinson's disease and brain injuries, are associated with the down-regulation of VEGF.[3] Some major expressed variants of VEGF isoforms from a single VEGF gene consist of 121, 145, 165, 183, 189 and 206 amino acids. Out of these six isoforms, VEGF165 is the most predominant VEGF-A isoform, which is over expressed in tumor cells during preliminary tumor growth phase, especially, in breast and lung cancers and possible predictor of cancers. The determination of the level of VEGF165 in blood, irrespective of their type, can be a fruitful approach to clinical diagnosis of cancer.[4]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call